Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.
To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.
为了为美国丙型肝炎病毒 (HCV) 筛查指南的拟议变更提供信息,我们使用之前发表的模型评估了对既往妊娠期间无 HCV 证据的女性进行 HCV 产前重新筛查的成本效益。对孕妇进行普遍的 HCV 重新筛查具有成本效益(增量成本效益比为每质量调整生命年 6000 美元),应在全国范围内推荐。